1.78%XLF 20.53 6.48%QQQQ 45.97 2.38%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
NEW YORK (AP) - Drug developer Inspire Pharmaceuticals Inc. said Friday it received a $1.3 million milestone payment for the dry eye treatment DE-089 from its Japanese partner Santen Pharmaceutical Co. Ltd.
| ISPH | 4.45 |  0.37 |
Inspire said it received the payment because Santen completed a late-stage trial of the drug, also known as diquafosol tetrasodium.
Santen expects to file an application for DE-089 with Japanese regulators by the end of June.
The two companies have an agreement to develop the drug in Asia, with Santen responsible for marketing once approved.
In the United States, DE-089 is known as Prolacria. The Food and Drug Administration has on two occasions, December 2003 and December 2005, declined to approve the drug.
Share of Inspire closed Thursday at $3.49.
The Euro was moving neutrally yesterday against the US Dollar between yesterday's top 1.5737 and the bottom 1.5640, which are the first resi...
On July 7th Carl Icahn issues a letter to the board of Yahoo. The following is the letter in full. <hr>
A decision by Britain's anti-corruption agency to halt an inquiry into a lucrative arms deal between Saudi Arabia and BAE Systems PLC reached Bri...
|
Find the most up to date research from leading investment firms to make the most informed investing decisions
Professional Website Design For Corporate - Get a Free Quote Today
Partners  
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
